seh

sEH inhibitor-3 (compound 35) is a potent, orally active inhibitor of soluble epoxide hydrolase (sEH), acting on human sEH with a Ki of 0.75 nM.

Dual FAAH sEH-IN-1 is a dual inhibitor of sEH (soluble epoxide hydrolase) (IC50: 9.6 nM) and FAAH (fatty acid amide hydrolase) (IC50: 7 nM) with high affinity and anti-inflammatory activity.

sEH inhibitor-7 is a soluble epoxide hydrolase (sEH) inhibitor that inhibits sEH in human and mouse with IC 50 s of 6.2 μM and 0.15 μM, respectively. sEH inhibitor-7 is associated with anti-inflammatory active molecules.

CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases the activity of peroxisome proliferator-activated receptor (PPAR) alpha. CUDA may be valuable for the study of cardiovascular diseases.

PTUPB is a potent dual inhibitor of sEH and COX-2 enzymes with IC50 values of 0.9 nM and 1.26 μM, respectively.

GSK2256294A (GSK 2256294) is potent, selective inhibitor of recombinant human, rat and mouse sEH with IC50 of 27 pM, 61 pM and 189 pM, respectively.

trans-AUCB (t-AUCB) is an effective and selective soluble epoxide hydrolase inhibitor, with IC50 values of 1.3 nM for hsEH, 8 nM for mouse sEH, and 8 nM for rat sEH.

TPPU is a potent inhibitor of both human and mouse sEH (IC50 of 3.7 and 2.8 nM, respectively)

beta-Amyrin acetate inhibits HMG-CoA Reductase (HMGCR) and sEH activity with IC50 of 3.4 μM. beta-Amyrin acetate has anti-inflammatory, antifungal, antioxidant, and anti-hyperlipidemic activities.

sEH-degrader-1 (Compound 8) acts as an effective inhibitor of sEH, exhibiting IC50 values of 3.8 nM for hsEH and 210 nM for msEH. Additionally, it proficiently degrades sEH in both mouse liver and brown adipose tissue.

sEH inhibitor-19 (Compound (R)-14i) is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 1.2 nM. This compound suppresses the expression of TNF-α and IL-6 and exhibits anti-inflammatory effects in mouse models of acute pancreatitis and Carrageenan-induced edema.

mPGES-1 sEH-IN-1 (compound 1f) is an sEH inhibitor with an IC50 value of 5 μM. It also exhibits antitumor activity by inhibiting mPGES-1, with an IC50 value of 25 µM.

sEH inhibitor-20 is a metabolically stable, orally active sEH inhibitor with an IC50 of 0.2 nM. It exhibits significant analgesic and anti-inflammatory properties, making it a promising candidate for researching neuropathic pain.

sEH-IN-12 is an effective inhibitor of the enzyme soluble epoxide hydrolase (sEH).

sEH inhibitor-6 (Compound 3g) is a highly potent soluble epoxide hydrolase (sEH) inhibitor, exhibiting an IC50 value of 0.5 nM [1].

SEH inhibitor-2 (compound 5l) is a soluble epoxide hydrolase (sEH) inhibitor with oral activity (IC50=0.9 nM), and the predicted oral absorption percentage is 71.2-88.4%. SEH inhibitor-2 can maintain a high concentration of eicosanoic acid (EETs) in serum. SEH inhibitor-2 has research value in cardiovascular protection.

COX-2 sEH-IN-1 is an orally active dual inhibitor of COX-2 (IC50: 1.24 μM) and sEH (IC50: 0.40 μM), a soluble epoxide hydrolase. COX-2 sEH-IN-1 increases anti-inflammatory effects and significantly reduces cardiovascular risk.

sEH inhibitor-4 (compound B15) has been identified as a potent soluble epoxide hydrolase (SEH) inhibitor with a remarkable inhibitory potency of 0.03 ± 0.01 nm. Intensive structural modification efforts led to the discovery of this compound for its ability to decrease inflammation and alleviate pain in the presence of SEH.

sEH inhibitor-5 is a potent inhibitor of sEH (soluble epoxide hydrolase) (IC50: 0.1 nM).

sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE) with potential research applications in Alzheimer's disease (AD) due to its cumulative effect against neuroinflammation and memory impairment.

sEH inhibitor-1 (compound TCPU) is a potent, orally active inhibitor of soluble epoxide hydrolase (sEH) with IC50 values of 0.4 and 5.3 nM for human and murine she, respectively.

sEH inhibitor-14, a benzoxazolone-5-urea analogue, acts as an efficient soluble Epoxide Hydrolase (sEH) inhibitor, demonstrating significant activity with an IC50 value of 0.39 nM.

sEH AChE-IN-2 and acetylcholinesterase ( AChE ). sEH AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .

sEH AChE-IN-3 (15) serves as a dual inhibitor targeting both soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), demonstrating potent activity and the ability to cross the blood-brain barrier (BBB). It exhibits IC50 values of 0.4 nM for human sEH (hsEH), 1.94 nM for human AChE (hAChE), 615 nM for human butyrylcholinesterase (hBChE), 4.3 nM for mouse sEH (msEH), and 2.61 nM for mouse AChE (mAChE), indicating its efficacy across these enzymes.